ERBB2 and breast cancer: In contrast, ER/PR–negatives and HER2/neu–positives, typically tumors of more aggressive nature, demonstrated younger DNAm age and decelerated epigenetic aging than their respective counterparts and those without BC; this finding is also consistent with those of prior reports [6, 8, 50].